Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Eric Klein MD

Eric A. Klein MD

Chairman, Glickman Urological & Kidney Institute, Cleveland, Ohio

Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate,  testis and kidney.  For several years, including the current edition, Dr. Klein is listed in Best Doctors in America.

Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He was the National Medical Study Coordinator for the National Cancer Institute sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic.

Dr. Klein received his medical degree from University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.

Disclosure: Dr. Klein receives, or has the right to receive, royalty payments for inventions or discoveries commercialized through the companies shown below):

Abbott Laboratories

Recent Contributions to PracticeUpdate:

  1. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men With PSA Persistence
  2. Concordance of Non–Low Risk Disease Among Pairs of Brothers With Prostate Cancer
  3. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy
  4. Biopsy-Based Genomic Classifier Able to Predict Distant Metastasis After Definitive Radiation and ADT for Prostate Cancer
  5. (68)Ga-PSMA PET/CT for Staging of Lymph Node Regions Prior to Lymph Node Dissection in Prostate Cancer
  6. DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy
  7. FSH Predicts Development of Castration-Resistant Prostate Cancer
  8. Long-Term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer
  9. Alcohol Negates Dutasteride-Mediated Protection From High-Grade Prostate Cancer
  10. FDA Panel Recommends Against Approval of Ultrasound Therapy for Early Prostate Cancer

Recently Updated